Bayspair is a dedicated technology provider, offering far more than standard genome editing services. All technologies in our portfolio are either fully owned or exclusively licensed with commercial sub-licensing rights. Genome-edited cells created through our services are not limited to research use, but are fully empowered for commercial application. We facilitate this transition through our seamless and reasonable licensing agreements for all collaborative projects.
Scarless Editing's core technology maximizes HDR (homologous recombination repair) based genome editing efficiency, achieving both high quality and low cost.
Bayspair owns a proprietary nuclease replacing CRISPR/Cas9. With 100% ownership, it's licensable for all applications—free from third-party restrictions.